Role of Ivermectin Nanosuspension as Nasal Spray in Treatment of Persistant Post covid19 Anosmia

Anosmia Clinical Trial

Official title:

Studying the Expected Effect of Ivermectin Nanosuspension as Nasal Spray Upon Post covid19 Persistant Anosmia

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT04951362
• Other study ID #: SVU MED CIT0 23 4 21 1 122
• Status: Recruiting
• Phase: Phase 2/Phase 3
• Start date: April 20, 2021
• Est. completion date: May 15, 2022

Study information

• Verified date: April 2022
• Source: South Valley University
• Contact: Zaky Aref, MD
• Phone: +201001771210
• Email: doctor.aref[@]hotmail.com
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

ivermectin is FDA approaved antiparasitic drug which is also claimed to be having potent in vitro antiviral effect,so we are tryying to study itsovid19 anosmia effect upon releiving post covid19 anosmia

Description:

ivermectin is FDA approaved antiparasitic drug which is also claimed to be having potent in vitro antiviral effect,so we are tryying to study itsovid19 anosmia effect upon releiving post covid19 anosmia as one of the most characteresic symptoms of covid19 infection

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 117
• Est. completion date: May 15, 2022
• Est. primary completion date: May 12, 2022
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 70 Years

Eligibility

Inclusion Criteria:

• post covid19 anosmia

• negative swab test for covid19

Exclusion Criteria:

• other types of anosmia ,

• no local or central other causes of anosmia

• still active covid 19 pateints ( positive swab test )

Related Conditions & MeSH terms

• Anosmia

Intervention

Drug:
• intranasal spray ivermectin
intranasal spray of saline

Locations

Country	Name	City	State
Egypt	Zaky Aref	Qina

Sponsors (1)

Lead Sponsor	Collaborator
South Valley University

Country where clinical trial is conducted

Egypt, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	regaining of smell	regaining of smell	within 14 days after enrollemen ]